PURPOSE: To describe physicians' observations and perceptions of patients with schizophrenia and to obtain information about antipsychotic prescribing practices. METHODS: Psychiatrists in the United States and five European countries (France, Germany, Italy, Spain, and the United Kingdom) who prescribed antipsychotics for >or=15 patients with schizophrenia within the preceding 3 months provided data on their patients' demographic and clinical characteristics and their antipsychotic prescribing practices and drug attributes influencing treatment choice. RESULTS: Data were collected from 872 physicians on 6523 patients (85% European, 15% US). Most patients were aged 25-44 years, 63% were men, and 66% were outpatients. About 50% of patients were moderately to grossly dysfunctional; about 50% were unemployed; 34% and 75% were taking conventional or atypical antipsychotics, respectively. Frequently identified positive symptoms included delusions (73%), disordered thought (59%), and hallucinations (59%); common negative symptoms included social withdrawal (54%), impoverished thought (39%), and blunted affect (38%). Reasons for antipsychotic selection included efficacy for positive (90%) or negative symptoms (62%) and tolerability (47%). Inadequate control was reported more frequently for negative (71-77%) than positive (47-60%) symptoms. Adverse events included sedation, weight gain, and extrapyramidal symptoms. CONCLUSIONS: In this large, multinational, cross-sectional survey, physicians reported that positive symptoms were more common than negative symptoms. Treatment for positive symptoms was more successful than that for negative symptoms, with physicians considering treatment inadequate for >70% of patients with negative symptoms.
PURPOSE: To describe physicians' observations and perceptions of patients with schizophrenia and to obtain information about antipsychotic prescribing practices. METHODS: Psychiatrists in the United States and five European countries (France, Germany, Italy, Spain, and the United Kingdom) who prescribed antipsychotics for >or=15 patients with schizophrenia within the preceding 3 months provided data on their patients' demographic and clinical characteristics and their antipsychotic prescribing practices and drug attributes influencing treatment choice. RESULTS: Data were collected from 872 physicians on 6523 patients (85% European, 15% US). Most patients were aged 25-44 years, 63% were men, and 66% were outpatients. About 50% of patients were moderately to grossly dysfunctional; about 50% were unemployed; 34% and 75% were taking conventional or atypical antipsychotics, respectively. Frequently identified positive symptoms included delusions (73%), disordered thought (59%), and hallucinations (59%); common negative symptoms included social withdrawal (54%), impoverished thought (39%), and blunted affect (38%). Reasons for antipsychotic selection included efficacy for positive (90%) or negative symptoms (62%) and tolerability (47%). Inadequate control was reported more frequently for negative (71-77%) than positive (47-60%) symptoms. Adverse events included sedation, weight gain, and extrapyramidal symptoms. CONCLUSIONS: In this large, multinational, cross-sectional survey, physicians reported that positive symptoms were more common than negative symptoms. Treatment for positive symptoms was more successful than that for negative symptoms, with physicians considering treatment inadequate for >70% of patients with negative symptoms.
Authors: Benedict Tak Wai Chong; Suzaily Wahab; Arunakiri Muthukrishnan; Kok Leong Tan; May Lee Ch'ng; Mei Theng Yoong Journal: Psychol Res Behav Manag Date: 2020-11-10
Authors: Miranda Bridgwater; Peter Bachman; Brenden Tervo-Clemmens; Gretchen Haas; Rebecca Hayes; Beatriz Luna; Dean F Salisbury; Maria Jalbrzikowski Journal: Psychol Med Date: 2020-10-06 Impact factor: 10.592
Authors: Christopher Gaudiot; Xiaoming Du; Ann Summerfelt; Stephanie M Hare; Juan R Bustillo; Laura M Rowland; L Elliot Hong Journal: J Abnorm Psychol Date: 2019-05-06
Authors: Andy Forbes; Mary Hobart; John Ouyang; Lily Shi; Stephanie Pfister; Mika Hakala Journal: Int J Neuropsychopharmacol Date: 2018-05-01 Impact factor: 5.176